Efficacy of early intravesical instillation of hyaluronic acid after transurethral resection of non-muscle-invasive bladder cancers: An open-label, prospective, single-center, randomized, controlled and parallel-group pilot study
Authors:
Open Access
- 3 February 2026
- journal article
- special topic
- Published by Wolters Kluwer Health in Current Urology
- Vol. 20 (2) , 117-124
Abstract
Background: Lower urinary tract symptoms (LUTS) and pain are clinically relevant problems after transurethral resection (TURBT) of nonmuscle-invasive bladder cancer. Although intravesical instillation of hyaluronic acid has already been proven to be a valid treatment for storage LUTS and pain in patients with inflammatory bladder syndrome, its efficacy in patients who undergo TURBT is unknown. This study aimed to present the results of a prospective, randomized, controlled, clinical pilot study on the safety and clinical performance of HydealCyst (Fidia Farmaceutici S.p.A., Italy), a device formulated to provide progressive, long-lasting intravesical release of hyaluronic acid. Materials and methods: Adults diagnosed with nonmuscle-invasive bladder cancer and scheduled for TURBT were included and underwent 4 visits up to 25 days after TURBT. Of the 47 patients who completed the investigation, 25 participants received 2 postoperative intravesical instillations with HydealCyst. The efficacy of HydealCyst on storage LUTS, pain, urinary symptoms, and patients’ quality of life was evaluated using validated questionnaires. Results: Although the overall LUTS were similar in the 2 experimental groups, lower micturition frequency and fewer daytime micturitions were observed in patients treated with HydealCyst. These patients also showed a significant reduction in pain ( p = 0.03) 3 days after catheter removal and better quality of life at the end of the study. The device was well tolerated, with no treatment-emergent adverse events of severe intensity. Conclusion: The results from this pilot study indicate a clinically meaningful improvement of symptoms after 2 instillations of HydealCyst, supporting this intervention as a potentially effective treatment for LUTS and pain after TURBT.Keywords
This publication has 31 references indexed in Scilit:
- Voiding function improves under long-term testosterone treatment (TTh) in hypogonadal men, independent of prostate sizeInternational Urology and Nephrology, 2023
- The role of bladder instillation in the treatment of bladder pain syndrome: Is intravesical treatment an effective option for patients with bladder pain as well as LUTS?International Urogynecology Journal, 2020
- Observation and mechanism study of bladder wound healing after transurethral holmium laser resection of bladder tumorLasers in Medical Science, 2019
- Increased risks of healthcare-seeking behaviors of anxiety, depression and insomnia among patients with bladder pain syndrome/interstitial cystitis: a nationwide population-based studyInternational Urology and Nephrology, 2015
- Quality of diagnostic staging in patients with bladder cancer: A process‐outcomes linkCancer, 2014
- Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country studyQuality of Life Research, 2012
- Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome/interstitial cystitisInternational Urogynecology Journal, 2011
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Hyaluronan treatment of interstitial cystitis/painful bladder syndromeInternational Urogynecology Journal, 2007
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002